University launches tender for next-generation sequencing platform
A university is tendering for a new sequencing platform, signalling rising demand for advanced genomic research infrastructure across the sector.
A university is tendering for a new sequencing platform, signalling rising demand for advanced genomic research infrastructure across the sector.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.
Next Generation Sequencing Platform is a new contract notice from Univerzita Karlova for the supply and installation of a DNA sequencing analysis device, a DNA fragmentation device and related servers. The investment is intended to support advanced genomic research and analysis, with clear potential to strengthen the university’s work on complex and rare conditions.
Published on 3rd June 2026, the notice from Univerzita Karlova sets out a compact but telling scope. The university is not only buying a DNA sequencing analysis device, but also a DNA fragmentation device and the servers needed to handle the resulting data.
Taken together, these components point to an end-to-end workflow, from fragmentation of DNA through sequencing to computational analysis. Rather than relying on external facilities for key stages, Univerzita Karlova appears to be consolidating capability within its own infrastructure.
The notice does not yet specify technical performance criteria such as throughput, read type or target applications. What it does emphasise is that the platform will serve “advanced genomic research and analysis”. That phrasing suggests ambitions that go beyond routine assays towards more complex projects, including work on difficult-to-diagnose and rare diseases where detailed genomic insight is often critical.
The inclusion of related servers is significant. Several recent tenders across the sector show that sequencing buyers now think about data infrastructure and analysis software at the same time as instruments. By bundling compute capacity into this contract, the university is signalling that bioinformatics capability is as central to the platform as the wet-lab hardware.
The move by Univerzita Karlova comes amid a cluster of recent procurements for next-generation sequencing systems, services and data platforms across research institutes, hospitals and health agencies.
In June 2026, EPFL-Scientific Equipment issued a contract notice for a high-throughput DNA sequencing platform for its Gene Expression Core Facility, to support advanced functional genomics research with a focus on RNA-seq, epigenomic profiling and genome sequencing. In March 2026, AGES - Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH sought the delivery, assembly, installation and commissioning of a new advanced Next Generation Sequencing System, highlighting the continued modernisation of national reference laboratories.
Also in March 2026, Instytut Biologii Doświadczalnej im. M.Nenckiego PAN tendered for a high-throughput sequencing workstation and an emulsion-digital PCR system, with explicit requirements for technical capabilities and compatibility with existing infrastructure. And in May 2026, Université de Montpellier launched a contract for a high-throughput long fragment sequencer for the MGX-NGS platform at Biocampus, funded by CPER DiAMs.
Clinical and translational centres are moving in parallel. On 12th March 2026, Fakultní nemocnice Motol a Homolka advertised the supply and installation of devices for high-precision whole-genome and whole-transcriptome sequencing to equip a Scientific and Diagnostic Oncology Center. On 18th March 2026, Országos Onkológiai Intézet sought a high-performance sequencing device under a rental agreement to support molecular diagnostics, requiring capabilities for a range of genomic analyses and full maintenance during the rental period.
Projects focused on research networks are also evident. On 20th February 2026, Universitatea de Medicina si Farmacie "Carol Davila" went to market for the supply and installation of high-throughput and portable genomic sequencing systems, together with accessory services, to serve several medical research institutions. On 24th March 2026, Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy announced the delivery of a system of laboratory devices, including a sequencer and nucleic acid isolation device, for next-generation sequencing studies as part of the Clinical Research Support Center for Western Mazovia project.
Viewed against this backdrop, Univerzita Karlova’s new platform looks less like an isolated upgrade and more like part of a broader push to expand genomic infrastructure across research and clinical settings.
One feature of recent notices is the variety of commercial and technical models being used to secure sequencing capacity. Univerzita Karlova has opted for outright purchase and installation of equipment and servers. Other buyers are mixing hardware, rental, reagents, cloud and fully outsourced services.
In December 2025, Universitätsklinikum Halle (Saale) AöR issued a contract notice for an integrated sequencing device for Next Generation Sequencing, to be provided under a rental arrangement that includes consumables and personnel training, with an option to purchase after the rental period. On 18th May 2026, Uniwersyteckie Centrum Kliniczne combined the supply of laboratory reagents for next-generation sequencing with the leasing of an NGS sequencer, tying instrument access tightly to reagent provision.
Service-based models are also gaining ground. On 27th May 2026, Narodowy Instytut Leków commissioned NGS sequencing services in batches of 1 to 200 samples, covering quality checks, sequencing, bioinformatics analysis and regular progress updates. Earlier, in February 2026, UNIVERZITETNI KLINIČNI CENTER MARIBOR sought the implementation of next-generation sequencing services rather than devices, and on 13th February 2026 Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie went to market for a nucleic acid sequencing platform alongside an electrophoretic analysis system for NGS libraries and an automated system for preparing those libraries.
Cloud and software contracts add another layer. Meditsinski universitet-Varna "Prof. Dr Paraskev Iv. Stoyanov" published a notice on 22nd December 2025 for a 12-month access package to a cloud platform to manage sequencing processes and bioinformatics analysis, together with software for variant interpretation and data reporting for specific research projects. On 30th April 2026, Sieć Badawcza Łukasiewicz - PORT Polski Ośrodek Rozwoju Technologii released a prior information notice on the delivery, installation and commissioning of an integrated nucleic acid sequencing system featuring high-performance long-read sequencing, local data processing and dedicated software.
University buyers are also signalling how they expect suppliers to support equipment over its lifecycle. Pécsi Tudományegyetem’s April 2026 tender for a next-generation sequencing platform specified a 12-month warranty with free repair and maintenance, a five-year guarantee on spare parts availability, and mandatory delivery, installation, testing and user training. NPL Management Limited’s prior information notice from May 2026, covering a medium to high throughput DNA sequencer for routine molecular genetics workflows, highlighted reliable performance, ease of use and comprehensive service support as central requirements.
Against this mix of rentals, service contracts and cloud subscriptions, Univerzita Karlova’s decision to combine instruments and servers in a single purchase tender points to a deliberate emphasis on in-house capability and control.
Several recent procurements underline how fast genomic data volumes are rising and how closely sequencing investments are now tied to data management and analysis.
On 15th May 2026, Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. went out to tender for the planning and implementation of a scalable genome database for neurodegenerative diseases. The contract includes data processing and sequencing services for up to 25,000 long-read genomes, illustrating the scale of datasets that new infrastructure must handle.
Long-read technologies feature in multiple notices. Meditsinski universitet has requested consumables and reagents for long-read sequencing of the entire human genome, without specifying a particular manufacturer. Université de Montpellier’s CPER DiAMs-funded project focuses on a high-throughput long fragment sequencer, while the Łukasiewicz - PORT notice emphasises high-performance long-read sequencing with local data processing. Together, these projects show an appetite not just for higher throughput, but for more detailed and structurally informative genomic data.
Alongside these, more established methods continue to have a place. Masarykův onkologický ústav is procuring a genetic analyser for Sanger sequencing and fragment analysis, together with consumables, underlining that many laboratories will run Sanger and next-generation approaches in parallel for the foreseeable future.
The regional context around Univerzita Karlova is also changing. On 7th April 2026, Univerzita Karlova, 1. lékařská fakulta, published a notice for the delivery of a high-capacity desktop NGS sequencer for the Institute of Medical Biochemistry and Laboratory Diagnostics, including post-warranty service. On 2nd April 2026, Masarykova univerzita tendered for a system to analyse ultra-long DNA molecules for determining structural and numerical variants of the genome at its Preclinical Centre. These parallel investments indicate that universities in the region are building a layered sequencing ecosystem, from benchtop instruments and ultra-long-read platforms to shared oncology and clinical research centres.
For Univerzita Karlova, the combination of a DNA sequencing analysis device, a DNA fragmentation device and dedicated servers should position its researchers to contribute more fully to collaborations around cancer, neurodegenerative and rare disease genomics, where access to integrated wet-lab and data infrastructure is increasingly a prerequisite.
The Univerzita Karlova notice is concise, focusing on the core components of the platform rather than granular specifications or contract value. Potential suppliers and research partners will be watching for more detail on performance requirements, software environments, data security and interoperability with existing systems.
Given the wider pattern of tenders for reagents, cloud platforms, sequencing services and genome databases, further related procurements are likely to follow, whether for consumables, additional bioinformatics capacity or participation in shared data resources.
For now, the contract marks another step in a clear trajectory: sequencing and analysis infrastructure is moving from specialist corners of the system into the mainstream of university research and clinical collaboration, and Univerzita Karlova intends to be equipped to play a full part.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.